CORCEPT THERAPEUTICS INC
CORT · XNASCIK 1088856fmd_0ZYJFWWD5AM0TWNR31VXC6CY84Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2000 to Sep 30, 2026, 76 periods
Latest annual · FY2025
Millions- Total revenues
- 761
- Gross profit
- 748
- Operating income
- 45
- Net income
- 100
- Free cash flow
- 142
Latest quarter · Q3 FY2026
Millions- Total revenues
- 340
- Gross profit
- 336
- Operating income
- 115
- Net income
- 127
- Free cash flow
- 142
Daily close · CORTIEX trades only
Nov 13, 2025 to Nov 11, 2026 · 250 sessions74.49 USD
Built from trades executed at IEX only, one exchange with a small share of US volume. This is not the consolidated tape. The close is the last IEX trade of the session, not the official closing price. Earlier sessions are divided by the later split ratios the API confirmed against IEX prices; dividends are not adjusted. Switch to As traded for the prices as they printed. End of day, not real time: a session is published the day after it trades.
Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use. iex.io/legal/hist-data-terms
Key stats
Open AnalysisCompound annual growth
- Revenue, 3 yearsFY2022 to FY2025
- +23.7%
- Revenue, 5 yearsFY2020 to FY2025
- +16.6%
- Net income, 5 yearsFY2020 to FY2025
- -1.2%
CORCEPT THERAPEUTICS INC (CORT) financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2025 | FY2024 | Change | Source |
|---|---|---|---|---|
| Revenue | $761.4 million | $675 million | +12.8% | 10-K 2026-02-24 · proof |
| Gross profit | $748.4 million | $664.2 million | +12.7% | 10-K 2026-02-24 · proof |
| Operating income | $44.8 million | $137 million | -67.3% | 10-K 2026-02-24 · proof |
| Net income | $99.7 million | $141.2 million | -29.4% | 10-K 2026-02-24 · proof |
| Cash from operating activities | $142 million | $198.3 million | -28.4% | 10-K 2026-02-24 · proof |
| Free cash flow | $141.8 million | $196.1 million | -27.7% | 10-K 2026-02-24 · proof |
| Total assets | $836.7 million | $840.6 million | -0.5% | 10-K 2026-02-24 · proof |
| Total liabilities | $188.8 million | $161 million | +17.3% | 10-K 2026-02-24 · proof |
| Cash and cash equivalents | $120.5 million | $127.7 million | -5.6% | 10-K 2026-02-24 · proof |
- What was CORCEPT THERAPEUTICS INC (CORT)'s revenue in fiscal 2025?
- CORCEPT THERAPEUTICS INC (CORT) reported revenue of $761.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $675 million the year before (+12.8%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was CORCEPT THERAPEUTICS INC (CORT)'s gross profit in fiscal 2025?
- CORCEPT THERAPEUTICS INC (CORT) reported gross profit of $748.4 million for fiscal 2025 (the year ended Dec 31, 2025), against $664.2 million the year before (+12.7%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was CORCEPT THERAPEUTICS INC (CORT)'s operating income in fiscal 2025?
- CORCEPT THERAPEUTICS INC (CORT) reported operating income of $44.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $137 million the year before (-67.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was CORCEPT THERAPEUTICS INC (CORT)'s net income in fiscal 2025?
- CORCEPT THERAPEUTICS INC (CORT) reported net income of $99.7 million for fiscal 2025 (the year ended Dec 31, 2025), against $141.2 million the year before (-29.4%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was CORCEPT THERAPEUTICS INC (CORT)'s cash from operating activities in fiscal 2025?
- CORCEPT THERAPEUTICS INC (CORT) reported cash from operating activities of $142 million for fiscal 2025 (the year ended Dec 31, 2025), against $198.3 million the year before (-28.4%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What was CORCEPT THERAPEUTICS INC (CORT)'s free cash flow in fiscal 2025?
- CORCEPT THERAPEUTICS INC (CORT) reported free cash flow of $141.8 million for fiscal 2025 (the year ended Dec 31, 2025), against $196.1 million the year before (-27.7%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are CORCEPT THERAPEUTICS INC (CORT)'s total assets?
- As of Dec 31, 2025, CORCEPT THERAPEUTICS INC (CORT) reported total assets of $836.7 million, against $840.6 million a year earlier (-0.5%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are CORCEPT THERAPEUTICS INC (CORT)'s total liabilities?
- As of Dec 31, 2025, CORCEPT THERAPEUTICS INC (CORT) reported total liabilities of $188.8 million, against $161 million a year earlier (+17.3%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
- What are CORCEPT THERAPEUTICS INC (CORT)'s cash and cash equivalents?
- As of Dec 31, 2025, CORCEPT THERAPEUTICS INC (CORT) reported cash and cash equivalents of $120.5 million, against $127.7 million a year earlier (-5.6%). Source: the 10-K filed with the SEC on Feb 24, 2026. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=ticker:CORT&period_type=annual&limit=5"Information only, not investment advice.